The Effect of Ivabradine on the Human Atrial Myocardial Contractility in an In Vitro Study
Table 2
Contraction parameters.
Number of trials
Force of contraction before the treatment (mN)
Force of contraction (%)
Passive tension force (%)
Duration of contraction (%)
Time to peak (%)
Time to relax (%)
G0: control
5 × 2
1.3 ± 0.6
93.5 ± 4.7
95.5 ± 4.3
97.7 ± 7.9
95.4 ± 2.5
99.0 ± 12.6
G1: ivabradine (60 nM)
5 × 2
1.2 ± 0.5
94.1 ± 4.5
99.3 ± 8.1
99.3 ± 3.3
96.1 ± 4.5
102.1 ± 5.0
G2: ivabradine (200 nM)
5 × 2
1.1 ± 0.2
101.0 ± 4.1
94.6 ± 3.8
100.5 ± 1.6
96.7 ± 1.6
104.6 ± 3.2
G3: ivabradine (2 μM)
5 × 2
1.5 ± 0.9
108.9 ± 11.6
99.0 ± 1.6
98.8 ± 2.7
98.2 ± 2.9
99.2 ± 3.1
Total/average
20 × 2
1.3 ± 0.6
99.4 ± 9.1
97.1 ± 5.1
99.1 ± 4.3
96.6 ± 3.0
101.2 ± 7.0
The averages of the measured force of contraction (CF) before the treatment in all groups and with the relative changes all contraction parameters. A statistical relevance. Values were reported as mean ± standard deviation.
